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Ab s t r a c t
Introduction: Relevant aspects of Alzheimer’s disease (AD) can be modeled by
aluminium-maltolate injection into specific regions of the brain. The possible
role of berberine chloride (BC) as an anti-inflammatory agent in the brain has
been previously addressed.
Material and methods: Rabbits were divided into control (C), untreated lesion
(L) and BC-treated + lesion (L + BC) groups. Animals in L + BC received BC (50 mg/
kg) orally 1 day after surgery and daily for 2 weeks. The lesion was induced by
injection of 100 µl of either vehicle or water containing 25 mM aluminium-mal-
tol into intraventricular fissure. Weight loss, ataxia, paralysis and tremor were
monitored. For histopathology, Bielschowsky silver and H&E staining were
employed. β-Secretase activity in hippocampus was finally assessed.
Results: All L animals died on days 12-15 after lesion. Seven to 10 days after
lesion, abnormal symptoms as well as cachexia were seen in over 90% of cas-
es. L rabbits lost an average of 0.5 kg which was significant on days 10 and 12
(p < 0.05); this was not completely prevented by BC. Up to day 15, all L animals
had lost their lives (p < 0.001). BC treatment protected the hippocampus from
degeneration, altered the behavior and decreased the activity of β-site amyloid
precursor protein cleaving enzyme-1 (BACE-1).
Conclusions: Considering the findings in regard to physiological abilities, histo-
logical changes and BACE-1 activity in hippocampus changes, it is concluded
that BC treatment could be an effective therapy in restoring Al maltol-induced
behavioral derangements in the rabbit model of AD.
Key words: Alzheimer’s disease, berberine, hippocampus, aluminium maltolate, 
β-secretase.
Introduction
Alzheimer’s disease (AD) is an irreversible, progressive neuro-degener-
ative disorder that occurs gradually and results in memory loss. Unusual
behaviour is accompanied by three main structural changes in the brain
including diffuse loss of neurons, intracellular protein deposits termed
neurofibrillary tangles (NFT) consisting of hyperphosphorylated tau pro-
tein and extracellular protein deposits termed β-amyloid (Aβ) or senile
plaques, surrounded by dystrophic neuritis [1-3].
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Considerable research has additionally been per-
formed to investigate a large array of neuropro-
tective agents using animal models which mimic
such disorders. Currently, no effective treatment
has been proposed to modify the symptoms; how-
ever, understanding the molecular mechanism of
AD has opened new opportunities for successful
development of medicines that prevent the gener-
ation of Aβ. The β-amyloid peptides (Aβ40 and Aβ42)
are implicated in the pathogenesis of AD and are
derived from sequential proteolytic cleavage of amy-
loid precursor protein by β and γ-secretases [4].
Extensive efforts have been devoted to identifying
inhibitors of the secretases’ activities, aiming to
prevent the formation of Aβ. Various mechanisms
have been proposed to explain the pathway by
which Aβ induces various changes such as neuronal
cell death, including intracellular calcium accumu-
lation, disruption of cellular Ca2+ homeostasis, reac-
tive oxygen species and nitric oxide production, lipid
peroxidation, decreased membrane fluidity, alter-
ation of the cytoskeleton and nucleus, redox-active
iron, the inflammatory or autoimmune process and
increased sensitivity along an apoptosis–necrosis
continuum [5]. Berberine is an isoquinoline alkaloid
with a long history of medicinal use in China; it
exists in Rhizoma Coptidis (Huanglian), Hydrastis
canadensis (Goldenseal) and Cortex Phellodendri
(Huangbai) as the main active principle of the herbs,
with multiple pharmacological effects. It is an acetyl
cholinesterase inhibitor similar to galanthamine,
a drug used for AD treatment [6].
Due to the inflammation and oxidative stress in
the brain which leads to the activation of β-secre-
tase enzyme activity, we decided to investigate the
neuroprotective effect of berberine on enzyme activ-
ity of an Al-maltol-induced AD model in aged rabbits.
Material and methods
Animals
Twenty-four male New Zealand white rabbits 
(3-4 kg body weight) were provided by the Experi-
mental Animal Center of Razi Vaccine and Serum
Research Institute. They were subsequently housed
one per cage with free access to food and water,
and kept in a constant environment at the Medical
Sciences of Iran University Animal Lab (22 ±2°C, 
50 ±5% humidity, and 12-h light/dark cycle). Twelve
animals with the same specifications were also
used for pathological examinations.
Experimental protocol
The animals were randomly divided into three
groups: control (C), untreated lesion (L) and BC-
treated + lesion (L + BC). The injection consisted of
100 µl of 25 mM Al maltol [7] intraventricularly by
stereotactic surgery as explained by Bertholf et al.
[9] under general anaesthesia with sodium pento-
barbital (50 mg/kg, i.v.). After surgery, a fresh sus-
pension in saline solution of berberine chloride 
(50 mg/kg) (Sigma, St. Louis, MO, USA) was admin-
istered intragastrically once daily for 14 days [6] to
the L + BC group and other groups received the
vehicle, i.e. saline solution.
On days 4, 7, and 10, 1 control and 3 L animals
were sacrificed for histopathological examinations.
Animals were anaesthetized by a lethal dose of
sodium pentobarbital and, before death, were per-
fused through the left ventricle with fixative solu-
tion (10% phosphate-buffered formalin) [7]. The cra-
nium was dissected in order to remove the brain.
The brain was fixed at room temperature in 10%
phosphate-buffered formalin for 2 weeks. Sections
of frontal cortex, rostral and caudal hippocampus,
adjacent temporal cortex, midbrain, pons, medulla,
cerebellum, and cervical levels of spinal cord, were
trimmed, embedded in paraffin and mounted
before being stained using haematoxylin and eosin
(H + E) and Bielschowsky silver methods.
Measurements
β-Secretase activity and kinetic analysis were
measured using a quenched fluorescence assay,
with the synthetic peptide substrate (7-methoxy
coumarin-4-yl) acetyl-Ser-Glu-Val-Asn-Leu*Asp-Ala-
Glu-Phe-Arg-Lys (2,4-dinitrophenyl)-Arg-Arg-NH2 for
β-secretase [10]. It was purchased from Peptide
Institute Inc. Osaka, Japan. The inhibitory activity
of the test compounds on β-site amyloid precursor
protein cleaving enzyme-1 (BACE-1) was determined
based on the percentage decrease of the cleaved
substrate by the enzyme (Figure 1). The assay was
done with 7 nM BACE-1, 20 µM substrate and
20 mM sodium acetate (CH3COONa) at a pH of 4.5
provided by 0.1% Triton X-100 as assay buffer in
a total reaction volume of 100 µl. After incubation
for 60 min at 37°C, the reaction was stopped 
by addition of trichloroacetic acid. The N-terminal
cleavage fragment [(7-methoxy coumarin-4-yl)
acetyl-Ser-Glu-Val-Asn-Leu-OH] was analysed by
RP-HPLC with the detection of fluorescence inten-
sity (Ex, 328 nm; Em, 393 nm). 
Chemicals
All the materials used to isolate and character-
ize the  -secretase enzyme from the hippocampus
in the animal model were purchased from Sigma
Aldrich Company and used according to the man-
ufacturer’s instructions. The procedure was carried
out under ice-cold conditions with pre-chilled 
CelLytic MT mammalian tissue lyses/extraction
reagent, protease inhibitor cocktail, pre-chilled
micro homogenizer, microcentrifuge (12 000-
20 000*gmax) for 10 min at 4°C. The supernatant
was aliquoted and stored at –70°C until further use.
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Statistical analysis
Data were represented as mean ± SEM and the
results were subsequently analysed as absolute val-
ues (total integrated volume). The significance of
differences between control and other groups was
statistically analysed by one-way analysis of vari-
ance (ANOVA) and, whenever p < 0.05, by Bonfer-
roni’s t test. Whenever only two groups had to be
compared, unpaired Student’s t test was used. Dif-
ferences were considered statistically significant
whenever p < 0.05. 
Results
Behaviour, survival rate and weight loss
All animals in the L group died on days 12-15
after lesion induction while the others survived. In
4 out of 8 animals in the L group, more generalized
debilities, including abnormal posture, developed.
Seven to 10 days after lesion induction, the follow-
ing symptoms were seen in over 90% of the ani-
mals: ataxia, tremor, forward head tilting, hind limb
paralysis and decreased food access due to physi-
cal disability. Signs of cachexia (presence of fatty
serous tissue) were observed in this group at the
time of necropsy. Weight loss was significant in
the L group compared to the controls on days 10
and 12 (p < 0.05; Table I). L rabbits lost an average
of 0.5 kg, whereas the control group gained an aver-
age weight of 0.4 kg. Weight loss was not com-
pletely prevented by berberine and the decrease in
weight reached the level of significance on days 10
and 12 (p < 0.05) as well as on day 15, when all
L group animals had lost their lives (p < 0.001).
Histopathological findings
The intraventricular administration of Al-maltol
to the aged rabbits induced neuronal perikaryal
neurofibrillary accumulations (hereafter termed neu-
rofibrillary degeneration) in 50% of the animals in
4 days. These accumulations were argyrophilic after
7 days. One hundred percent of the rabbits devel-
oped neurofibrillary degeneration in one or more
areas of neuroaxis. Multiple levels of neuroaxis were
Figure 1. A – Micrographs of H&E 700 section through the hippocampus from animals that received Al(maltol)3 (25 mM)
intraventricular injection. Gliosis and encephalitis of the brain in the aged rabbits is also observed in the vascular region
(arrows). B – Amyloidal plaque and amyloidal deposition by arrows with argyrophilic neurofibrillary degeneration
(Bielschowsky’s silver method). C – Neurofibrillary tangles (arrows) throughout the neuron including the entire length of
the dendrites and throughout the axons including the terminals (Bielschowsky silver method). D – Apoptotic bodies
(arrows) through the hippocampus in CA3 region (H&E*700). E – Neuronal loss in CA3 area through hippocampus, L group
(A), control group (B). F – Neuronal loss (arrowhead) and apoptosis (arrow) in CA2 area through hippocampus in L group
(H + E*640)
A B C
D E F
Time of measurement Controls L group L + BC group
Day 0 (before surgery) 3.30 ±0.03 3.30 ±0.03 3.30 ±0.03
Day 7 3.35 ±0.04 3.25 ±0.04 3.30 ±0.05
Day 10 3.43 ±0.04 3.03 ±0.02* 3.11 ±0.04*
Day 12 3.48 ±0.04 2.80 ±0.07* 2.90 ±0.08*
Day 15 3.57 ±0.04 All dead 2.77 ±0.12**
Table I. Body weight of control, La and L + BCb groups of rabbits in kg (mean  ± SEM)
aL group – Aluminium maltol-induced lesion group, bL + BC group – Aluminium maltol-induced lesion + berberine chloride treated group, 
*p < 0.05, significantly different compared to the control group (Bonferroni’s t test),**p < 0.001, significantly different compared to the control
group (Student’s unpaired t test)
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examined in all animal groups using H&E and sil-
ver staining techniques. The Al-maltol-injected ani-
mals showed widespread neurofibrillary degene -
ration (NFD) in the cortical and subcortical
distribution. Proper placement of the intraventric-
ular catheter was histologically verified by sections
along the catheter tract; mild to moderate astrocy-
tosis, necrosis, and macrophages were found
around the intraparenchymal tract of the catheter
(Figures 1 A, 1 B and 1 C). The pyramidal neurons
were consistently affected in rostrocaudal whole
brain coronal sections in Al-maltol-injected rabbits.
The accumulation was maximal near the site of alu-
minium injection. Aβ deposition, neurofibrillary tan-
gles, apoptosis, apoptotic bodies, neuronal loss and
inflammation were also demonstrated close to the
cerebral cortex and hippocampus (Figures 1 D, 1 E
and 1 F). No abnormality was observed in the brain
micrographs of the control animals.
Biochemical findings
BACE-1 activity was detectable by RP-HPLC in
hippocampus of the aged rabbits. Measurement of
β-secretase activity in the hippocampus revealed
a 3.2-fold increase compared to the controls 
(p < 0.05; Figure 2). Approximately 40% of this
increase was prevented by berberine treatment 
(p < 0.05; Figure 2).
Discussion
In the present study, it was found that intra-
ventricular Al-maltol injection in the aged New
Zealand white rabbit may induce behavioural, bio-
chemical and neuro-pathological changes, similar
to what may happen in clinical AD. On the other
hand, treatment with BC can protect the hip-
pocampus from degenerative changes, increase the
behavioural indices and delay the AD model symp-
toms (observed in the L group) and decrease BACE-1
activity in the L + BC group compared with the
L group. 
Rabbits are particularly sensitive to the neuro-
toxic effects of aluminium and they may develop
severe neurological changes depending on the dose,
age and route of administration [7-9]. A serious con-
troversy still remains concerning the possible roles
of Al in neurodegenerative disorders. However,
Savory et al. believe that it is quite reasonable to
consider the Al-treated rabbit as an excellent mod-
el for mimicking the biochemical composition of the
neurofibrillary tangles of AD [9]. Al could also play
an important role in the stabilization or aggrega-
tion of Aβ peptides in the plaques, loss of neurons
and apoptosis in aged rabbits. Overall, the Al-
induced experimental AD in rabbits has provided
much useful information on several processes that
could share a common mechanism with the devel-
opment of neuro-degeneration in AD; hence, this
model may be valuable as more mechanistic
schemes are uncovered. Additionally, the model
could also be of considerable value in the identifi-
cation of early diagnostic markers and the devel-
opment of new strategies in the prevention and
treatment of AD.
In the present study, intra-ventricular injection
of Al-maltol in aged New Zealand white rabbits was
validated as a model for AD due to the neuro-
pathological features revealed after Bielschowsky’s
silver staining under the light microscope. Such
characteristic features included neuro-degenerative
lesions including Aβ deposition, neuro-fibrillary tan-
gle formation, oxidative stress, apoptosis (apoptotic
bodies), neuronal loss and inflammation. Moreover,
from the clinical point of view, rabbits showed pro-
gressive behavioural symptoms, including forward
head tilting, tremor, loss of appetite, weight loss
and paralysis. Increased β-secretase enzyme activ-
ity was another proof for the validity of the model
used in this study.
As found in our study, berberine chloride could
delay the behavioural changes and symptoms
(weight loss, tremor, ataxia and paralysis) in the
rabbit AD model. Berberine could also decrease the
cleaved substrate by approximately 40% as detect-
ed by RP-HPLC with fluorescence intensity; a sig-
nificant reduction in enzymatic activities was also
observed. Berberine has been used orally as an OTC
drug in China and its safety and efficacy after oral
administration have been generally accepted [6].
A few studies have demonstrated that berberine
activates macrophages and increases phagocytot-
ic function of, and IL-1 production by, murine peri-
toneal macrophages (PMΦ) [11, 12]. In addition,
berberine potentiates the non-specific immunity
and, hence, it may be used as a neuroprotective
agent in the prevention of AD. Berberine may
Figure 2. BACE-1 inhibitory activity of the test com-
pounds was determined based on the decrease of
the cleaved substrate by the enzyme. The result rep-
resents at least three independent experiments; the
cleaved substrate level was increased in the L group 
Values represent the means ± SEM of 6 male rabbits
(> 3 kg); *p < 0.05 when compared with the normal
(C) group
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decrease the expression of peroxisome prolifera-
tor-activated receptor γ isoform 2 (PPARγ2) mRNA
and protein, which is a negative regulator of inflam-
mation [13, 14]. In spite of the fact that it exagger-
ates the inflammatory response, berberine might
be beneficial to AD by ameliorating spatial memo-
ry impairment, improving the expression of inflam-
matory factors, activating microglia and clearing
senile plaque [6].
In conclusion, we conclude that aged rabbits
treated with Al-maltol can serve as a suitable mod-
el of AD. Furthermore, oral administration of berber-
ine chloride can protect CNS cells in AD, caused by
inflammation and oxidative stress; anti-inflamma-
tory effects, inhibition of acetylcholine esterase and,
to some extent, β-secretase inhibition may be the
underlying mechanisms. However, further investi-
gations and clinical research are required to demon-
strate the efficacy of berberine in AD patients.
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